No profile data available.
Atea Pharmaceuticals, Inc. (AVIR) is a healthcare company in the antiviral pharmaceuticals industry, based in Boston, United States, with about 55 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$158.35 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $413.05 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Atea Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$413.05 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Vir Biotechnology, Inc. (VIR), Valneva SE (VALN), Assembly Biosciences, Inc. (ASMB), Arcturus Therapeutics Holdings Inc. (ARCT).